Valvular heart disease: A call for global collaborative research initiatives

Heart

Volumn 99, Issue 24, 2013, Pages 1797-1799

  Chambers, John B ^a   Shah, Benoy N ^b   Prendergast, Bernard ^c   Lawford, Patricia V ^d   McCann, Gerry P ^e   Newby, David E ^f   Ray, Simon ^g   Briffa, Norman ^h   Shanson, David ⁱ   Lloyd, Guy ^j   Hall, Roger ^k  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^g MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^h NORTHERN GENERAL HOSPITAL   (United Kingdom)

ⁱ GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^j EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

^k NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VASODILATOR AGENT;

AORTA DISEASE; AORTA STENOSIS; AORTA VALVE REGURGITATION; BACTERIAL ENDOCARDITIS; CARDIAC RESYNCHRONIZATION THERAPY; DENTAL PROCEDURE; EDITORIAL; HEART MUSCLE FIBROSIS; HEART VALVE PROSTHESIS; HUMAN; INTERDISCIPLINARY RESEARCH; MARFAN SYNDROME; MINIMALLY INVASIVE SURGERY; MITRAL ANNULOPLASTY; MITRAL VALVE REGURGITATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; THERAPY EFFECT; TRICUSPID ANNULOPLASTY; VALVULAR HEART DISEASE; WATCHFUL WAITING;

VALVULAR DISEASE;

CARDIOVASCULAR AGENTS; ENDOCARDITIS, BACTERIAL; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MORBIDITY; WORLD HEALTH;

EID: 84888019638     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-303964     Document Type: Editorial

References (20)

1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005-11.
2. Carapetis JR, Steer AC, Mulholland EK, et al. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005;5:685-94.
3. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease. Eur Heart J 2012;33:2451-96.
4. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55.
5. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol 2009;54:1003-11.
6. Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005;353:1342-9.
7. Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med 1994;331:689-94.
8. Stewart RA, Raffel OC, Kerr AJ, et al. Pilot study to assess the influence of beta-blockade on mitral regurgitant volume and left ventricular work in degenerative mitral valve disease. Circulation 2008;118:1041-6.
9. Nadir MA, Wei L, Elder DH, et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol 2011;58:570-6.
10. Kang DH, Park SJ, Rim JH, et al. Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation 2010;121:1502-9.
11. Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe aortic stenosis. Circulation 2010;121:151-6.
12. Lancellotti P, Lebois F, Simon M, et al. Prognostic importance of quantitative exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation 2005;112(Suppl):I377-82.
13. Dweck MR, Joshi S, Murigu T, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol 2011;58:1271-9.
14. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2006;48:e1-148.
15. Bach DS, Bolling SF. Improvement following correction of secondary mitral regurgitation in end-stage cardiomyopathy with mitral annuloplasty. Am J Cardiol 1996;78:966-9.
16. National Institute for Health and Clinical Excellence. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. NICE Clinical Guideline 64 2008. http://www.nice.org.uk/nicemedia/live/11938/40039/ 40039.pdf (accessed 1 Mar 2013).
17. Kang DH, Kim YJ, Kim SH, et al. Early surgery versus conventional treatment for infective endocarditis. New Engl J Med 2012;366:2466-73.
18. Mayosi B, Robertson K, Volmink J, et al. The Drakensberg declaration on the control of rheumatic fever and rheumatic heart disease in Africa. S African Med J 2006;96:246.
19. Bridgewater B, Kinsman R, Walton P, et al. Demonstrating quality: The Sixth National Adult Cardiac Surgical Database Report on behalf of the Society for Cardiothoracic Surgeons in Great Britain and Ireland. Henley-upon-Thames, UK: Dendrite Clinical Systems Ltd, 2009: 1-516.
20. Chambers J, Ray S, Prendergast B, et al. Specialist valve clinics: recommendations from the British Heart Valve Society working group on improving quality in the delivery of care for patients with heart valve disease. Heart 2013;99:1714-16.